Nicox Secures a €6M Shareholder Loan over 3 Years with Vester Finance
Nicox announced on Tuesday the signing of a shareholder loan agreement with Vester Finance for €6 million over 36 months. This optional financing aims to support the biotech's strategic opportunities while preserving its capital structure.
Nicox and Vester Finance have concluded a shareholder loan agreement signed on June 22, 2026, providing the company with additional resources of up to €6M over a three-year period. The arrangement operates on the basis of successive advances, each capped at €500K, which Nicox can request at its discretion without any obligation to draw.
Repayment in Shares or Cash, with a Dilution Cap
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Advances can be repaid either by subscribing to new shares issued by Nicox or in cash. In the case of repayment in shares, the issuance will be based on the lower of the two daily volume-weighted average prices preceding each issue, reduced by a maximum discount of 6.5%, up to a limit of 15 million new shares.
Clinical Advancements and Strategic Flexibility
Gavin Spencer, CEO of Nicox, stated that this financing line offers additional flexibility to explore strategic opportunities while maintaining a stable capital base. Nicox emphasizes that this shareholder operation functions in parallel with the unsecured bond financing announced on January 5, 2026.
Nicox a significativement renforcé sa position financière en 2025.
Risks mentioned
Baisse potentielle de la demande pour les nouveaux produits.
Risque de retard dans les soumissions réglementaires.
Opportunities identified
Soumission prévue de la NDA de NCX 470 aux États-Unis en été 2026.
Initiation du programme clinique de phase 3 pour NCX 470 au Japon.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
